Related Experiment Video
Updated: Apr 12, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Posaconazole: promising but problematic in practice in pediatric patients
Amanda Gwee1, Noel Cranswick, Nigel Curtis
1From the *Infectious Diseases and Australian Paediatric Pharmacology Research Unit, The Royal Children's Hospital Melbourne; and †Murdoch Children's Research Institute; and ‡Department of Paediatrics, The University of Melbourne, Victoria, Australia.
Abstract:
Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of invasive fungal infections. It is currently only licensed for use in children greater than 12 years of age. Absorption of the oral formulation is unpredictable and affected by mucositis and concomitant medications. We reviewed studies of posaconazole use in children younger than 12 years in relation to attainment of target serum concentrations.
More Related Videos
09:06Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research
Published on: March 29, 2024
12:29Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Dosing: Infants and Children
Antifungal Agents